

Table SI. Combination therapies prescribed in the study cohort

| Combination therapy <sup>a</sup>                                   | n (%)   |
|--|---------|
| Combinations of traditional systemic medications with phototherapy |         |
| Acitretin + topical psoralene plus UVA                             | 1 (0.5) |
| Fumaric acid esters + UVB 311 nm                                   | 3 (1.5) |
| Combinations of biologicals with traditional systemic medications  |         |
| Adalimumab + methotrexate  | 2 (1.0) |
| Etanercept + methotrexate  | 1 (0.5) |
| Golimumab + methotrexate   | 1 (0.5) |
| Infliximab + methotrexate <sup>a</sup>                             | 9 (4.5) |
| Infliximab + methotrexate + UVB 311 nm                             | 1 (0.5) |
| Combination including two biologicals <sup>b</sup>                 |         |
| Adalimumab + ustekinumab + methotrexate + UVB 311 nm               | 1 (0.5) |

All combinations were prescribed off-label with informed consent. Combinations including topical treatments were not mentioned.

<sup>a</sup>Infliximab was routinely administered in combination with low dose methotrexate. Respondents on this combination were grouped into the category "infliximab".

<sup>b</sup>One patient with extraordinarily severe and refractory psoriasis who had not responded to any biological monotherapy approved for psoriasis was treated with this quadruple combination.